Handbook of Pharmaceutical Manufacturing Formulations, Vol 6 Sterile Products

An authoritative and practical guide to the art and science of formulating drugs. With thoroughly revised and expanded content, this Second Edition six-volume set compiles volumes from FDA New Drug Applications, patent applications, and other sources of generic and proprietary formulations to cover the broad spectrum of issues concerning drug manufacturing. A must-have collection for pharmaceutical manufacturers, educational institutions, and regulatory authorities, this set is an excellent platform for drug companies to benchmark their products and for generic companies to formulate drugs coming off patent. As the largest reference on pharmaceutical formulations, this handbook also provides guidelines on how to file aNDAs in the shortest possible time, helping pharmaceutical companies to cut costs in the areas of pharmaceutical research and development. Divided conveniently into two parts—regulatory and manufacturing guidelines, and formulations—each volume in the set covers: cGMP compliance pre-approval inspections stability and bioequivalence testing packaging commodity development common difficulties in formulating drugs changes to aNDAs

An authoritative and practical guide to the art and science of formulating drugs.

With thoroughly revised and expanded content, this Second Edition six-volume set compiles volumes from FDA New Drug Applications, patent applications, and other sources of generic and proprietary formulations to cover the broad spectrum of issues concerning drug manufacturing.

A must-have collection for pharmaceutical manufacturers, educational institutions, and regulatory authorities, this set is an excellent platform for drug companies to benchmark their products and for generic companies to formulate drugs coming off patent.

As the largest reference on pharmaceutical formulations, this handbook also provides guidelines on how to file aNDAs in the shortest possible time, helping pharmaceutical companies to cut costs in the areas of pharmaceutical research and development.

Divided conveniently into two parts-regulatory and manufacturing guidelines, and formulations-each volume in the set covers:

• cGMP compliance
• pre-approval inspections
• stability and bioequivalence testing
• packaging commodity development
• common difficulties in formulating drugs
• changes to aNDAs

No other area of regulatory compliance receives more attention and scrutiny by regulatory authorities than the regulation of sterile products, for obvious reasons. With the increasing number of potent products, particularly the new line of small protein products, joining the long list of proven sterile products, the technology of manufacturing sterile products has evolved into a very sophisticated industry.

Highlights from Sterile Products, Volume Six include:

• formulations of sterile dosage forms, regulatory filing requirements of sterile preparations, and cGMP compliance, all of which are tied together in the final preparation of the CMC sections of regulatory applications
• specifications of a manufacturing facility to manufacture compliant sterile products
• NDA or aNDA filing requirements of sterile products
• an alphabetical presentation of formulations of pharmaceutical products based on their generic names

The largest category of pharmaceutical formulations, comprising almost two-thirds of all dosage forms, compressed solids present some of the greatest challenges to formulation scientists. The first volume, Compressed Solid Products, tackles these challenges head on.

Highlights from Compressed Solid Products, Volume One include:

• formulations for more than 200 of the most widely used drugs for all types of release profiles, offering formulators a rare opportunity to start with an optimal composition
• the essentials of what you need to be aware of when establishing a manufacturing process based on the formulations presented
• identification and inclusion of the most popular prescription products, a critical list for the selection of products

providing Methodologies That Can Serve As A Reference Point For New Formulations, The Second Volume Covers Uncompressed Solids, Which Include Formulations Of Powders, Capsules, Powders Ready For Reconstitution, And Other Similar Products.

highlights From Uncompressed Solid Products, Volume Two Include:

• the Fundamental Issues Of Good Manufacturing Practices


• formulations For More Than 400 Pharmaceutical Products, Including Currently Approved Products And Innovative Products Such As Small Proteins, Instantly Liquifiable Powders, And Nanoparticles


• access To Us Fda Guidelines, As Well As All Major Guidelines Around The World


• identification And Inclusion Of The Most Often Approved Capsules And Powders In The Us

the Fourth Volume In The Series Covers The Techniques And Technologies Involved In The Preparation Of Semisolid Products Such As Ointments, Creams, Gels, Suppositories, And Special Topical Dosage Forms. Drug Manufacturers Need A Thorough Understanding Of The Specific Requirements That Regulatory Agencies Impose On The Formulation And Efficacy Determination Of Drugs Contained In These Formulations.

highlights From Semisolid Products, Volume Four Include:

• coverage Of Over 350 Formulations


• valuable Information On The Difficult Area Of Compliance


• changes To Approved New Drug Applications And Abbreviated New Drug Applications


• the Evolving Guidelines Of Ich And When To Conduct A Regulatory Review

While liquid drugs do not share the compression problems of solid dosage forms, the filling problems of powder dosage forms, or the consistency problems of semisolid dosage forms, they do have their own set of considerations in the formulation and manufacturing stages.

Highlights from Liquid Products, Volume Three include:

• practical details involved in complying with the current good manufacturing practice requirements in liquid manufacturing
• access to what an FDA auditor would be looking for during a liquid manufacturing audit
• issues that may arise during a US FDA inspection
• the protocols used for stability testing for new drugs and new dosage forms, drawn from the most current ICH guidelines

Annotation Providing methodologies that can serve as a reference point for new formulations, the second volume covers uncompressed solids, which include formulations of powders, capsules, powders ready for reconstitution, and other similar products. Highlights from Uncompressed Solid Products, VolumeTwo include: the fundamental issues of good manufacturing practices formulations for more than 400 pharmaceutical products, including currently approved products and innovative products such as small proteins, instantly liquifiable powders, and nanoparticles access to US FDA guidelines, as well as all major guidelines around the world identification and inclusion of the most often approved capsules and powders in the US

Over-the-Counter products comprise a special category of healthcare products. While these formulations have much in common with their prescription counterparts, they are presented in this series separately because of their development approach taken, labeling considerations required, and support available from suppliers of ingredients in designing these products.

Highlights from Over-the-Counter Products, Volume Five include:

• solids, liquids, and suspensions
• practical advice on how to bring manufacturing practices into compliance with regulatory requirements
• cGMP considerations in great detail
• a large number of formulations of coatings of solid dosage forms

Annotation While liquid drugs do not share the compression problems of solid dosage forms, the filling problems of powder dosage forms, or the consistency problems of semisolid dosage forms, they do have their own set of considerations in the formulation and manufacturing stages. Highlights from Liquid Products, VolumeThree include: practical details involved in complying with the current good manufacturing practice requirements in liquid manufacturing access to what an FDA auditor would be looking for during a liquid manufacturing audit issues that may arise during a US FDA inspection the protocols used for stability testing for new drugs and new dosage forms, drawn from the most current ICH guidelines v. 1. Compressed solid products v. 2. Uncompressed solid products v. 3. Liquid products v. 4. Semisolid products v. 5. Over-the-counter products v. 6. Sterile products.